This inventor holds 4 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Oncotherapy Science, Incorporated, Kumamoto University. Active years: 2011-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011-2015
Title: Yoshiaki Ikuta: Innovator in Tumor Immunotherapy
Introduction
Yoshiaki Ikuta is a notable inventor based in Kumamoto, Japan. He has made significant contributions to the field of tumor immunotherapy, particularly through his innovative research and development of peptides derived from the SPARC protein.
Latest Patents
Ikuta holds 4 patents, with his latest invention focusing on SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same. The objective of this invention is to identify SPARC protein-derived peptides that can induce human killer T cells and helper T cells with cytotoxic activity against tumors. This advancement aims to provide a means for conducting tumor immunotherapy for patients suffering from various types of cancers that overexpress SPARC.
Career Highlights
Throughout his career, Yoshiaki Ikuta has worked with prominent organizations such as Oncotherapy Science, Incorporated and Kumamoto University. His work has been pivotal in advancing the understanding and treatment of cancer through immunotherapy.
Collaborations
Ikuta has collaborated with esteemed colleagues, including Yasuharu Nishimura and Shuichi Nakatsuru, contributing to the collective effort in cancer research and treatment.
Conclusion
Yoshiaki Ikuta's innovative work in the field of tumor immunotherapy highlights his commitment to advancing medical science. His contributions through patents and collaborations continue to impact the fight against cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile